Show simple item record

IL‐4 induces proliferation in prostate cancer PC3 cells under nutrient‐depletion stress through the activation of the JNK‐pathway and survivin up‐regulation

dc.contributor.authorRoca, Hernanen_US
dc.contributor.authorCraig, Matthew J.en_US
dc.contributor.authorYing, Chien_US
dc.contributor.authorVarsos, Zachary S.en_US
dc.contributor.authorCzarnieski, Paulen_US
dc.contributor.authorAlva, Ajjai S.en_US
dc.contributor.authorHernandez, Jamesen_US
dc.contributor.authorFuller, Daviden_US
dc.contributor.authorDaignault, Stephanie D.en_US
dc.contributor.authorHealy, Patrick N.en_US
dc.contributor.authorPienta, Kenneth J.en_US
dc.date.accessioned2012-04-04T18:42:43Z
dc.date.available2013-06-11T19:15:42Zen_US
dc.date.issued2012-05en_US
dc.identifier.citationRoca, Hernan; Craig, Matthew J.; Ying, Chi; Varsos, Zachary S.; Czarnieski, Paul; Alva, Ajjai S.; Hernandez, James; Fuller, David; Daignault, Stephanie; Healy, Patrick N.; Pienta, Kenneth J. (2012). "IL‐4 induces proliferation in prostate cancer PC3 cells under nutrient‐depletion stress through the activation of the JNK‐pathway and survivin up‐regulation ." Journal of Cellular Biochemistry 113(5): 1569-1580. <http://hdl.handle.net/2027.42/90542>en_US
dc.identifier.issn0730-2312en_US
dc.identifier.issn1097-4644en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90542
dc.description.abstractInterleukin (IL)‐4 plays a critical role in the regulation of immune responses and has been detected at high levels in the tumor microenvironment of cancer patients where it correlates with the grade of malignancy. The direct effect of IL‐4 on cancer cells has been associated with increased cell survival; however, its role in cancer cell proliferation and related mechanisms is still unclear. Here it was shown that in a nutrient‐depleted environment, IL‐4 induces proliferation in prostate cancer PC3 cells. In these cells, under nutrient‐depletion stress, IL‐4 activates mitogen‐activated protein kinases (MAPKs), including Erk, p38, and JNK. Using MAP‐signaling‐specific inhibitors, it was shown that IL‐4‐induced proliferation is mediated by JNK activation. In fact, JNK‐inhibitor‐V (JNKi‐V) stunted IL‐4‐mediated cell proliferation. Furthermore, it was found that IL‐4 induces survivin up‐regulation in nutrient‐depleted cancer cells. Using survivin‐short‐hairpin‐RNAs (shRNAs), it was demonstrated that in this milieu survivin expression above a threshold limit is critical to the mechanism of IL‐4‐mediated proliferation. In addition, the significance of survivin up‐regulation in a stressed environment was assessed in prostate cancer mouse xenografts. It was found that survivin knockdown decreases tumor progression in correlation with cancer cell proliferation. Furthermore, under nutrient depletion stress, IL ‐4 could induce proliferation in cancer cells from multiple origins: MDA‐MB‐231 (breast), A253 (head and neck), and SKOV‐3 (ovarian). Overall, these findings suggest that in a tumor microenvironment under stress conditions, IL‐4 triggers a simultaneous activation of the JNK‐pathway and the up‐regulation of survivin turning on a cancer proliferation mechanism. J. Cell. Biochem. 113: 1569–1580, 2012. © 2011 Wiley Periodicals, Inc.en_US
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.subject.otherJNKen_US
dc.subject.otherIL‐4en_US
dc.subject.otherPROLIFERATIONen_US
dc.subject.otherNUTRIENT‐DEPLETION STRESSen_US
dc.subject.otherPROSTATE CANCERen_US
dc.subject.otherSURVIVINen_US
dc.titleIL‐4 induces proliferation in prostate cancer PC3 cells under nutrient‐depletion stress through the activation of the JNK‐pathway and survivin up‐regulationen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelGeneticsen_US
dc.subject.hlbsecondlevelMolecular, Cellular and Developmental Biologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.subject.hlbtoplevelScienceen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Internal Medicine, Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan 48109en_US
dc.contributor.affiliationumDepartment of Urology, Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan 48109en_US
dc.contributor.affiliationumDepartment of Urology, Comprehensive Cancer Center, University of Michigan, 1500 E Medical Center Dr, 7431 CCC, Ann Arbor, MI 48109.en_US
dc.contributor.affiliationumDivision of Biostatistics, Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan 48109en_US
dc.identifier.pmid22174091en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90542/1/24025_ftp.pdf
dc.identifier.doi10.1002/jcb.24025en_US
dc.identifier.sourceJournal of Cellular Biochemistryen_US
dc.identifier.citedreferenceRoca H, Varsos ZS, Mizutani K, Pienta KJ. 2008b. CCL2, survivin and autophagy: New links with implications in human cancer. Autophagy 4: 969 – 971.en_US
dc.identifier.citedreferenceGooch JL, Lee AV, Yee D. 1998. Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res 58: 4199 – 4205.en_US
dc.identifier.citedreferenceGordon S. 2003. Alternative activation of macrophages. Nature reviews. Immunology 3: 23 – 35.en_US
dc.identifier.citedreferenceGordon S, Martinez FO. 2010. Alternative activation of macrophages: Mechanism and functions. Immunity 32: 593 – 604.en_US
dc.identifier.citedreferenceGuha M, Plescia J, Leav I, Li J, Languino LR, Altieri DC. 2009. Endogenous tumor suppression mediated by PTEN involves survivin gene silencing. Cancer Res 69: 4954 – 4958.en_US
dc.identifier.citedreferenceHui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, Komnenovic V, Scheuch H, Beug H, Wagner EF. 2007. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK‐c‐Jun pathway. Nat Genet 39: 741 – 749.en_US
dc.identifier.citedreferenceJenkins DE, Yu SF, Hornig YS, Purchio T, Contag PR. 2003. In vivo monitoring of tumor relapse and metastasis using bioluminescent PC‐3M‐luc‐C6cells in murine models of human prostate cancer. Clin Exp Metastasis 20: 745 – 756.en_US
dc.identifier.citedreferenceJeyaprakash AA, Klein UR, Lindner D, Ebert J, Nigg EA, Conti E. 2007. Structure of a Survivin‐Borealin‐INCENP core complex reveals how chromosomal passengers travel together. Cell 131: 271 – 285.en_US
dc.identifier.citedreferenceJochum W, Passegue E, Wagner EF. 2001. AP‐1 in mouse development and tumorigenesis. Oncogene 20: 2401 – 2412.en_US
dc.identifier.citedreferenceKawakami M, Kawakami K, Stepensky VA, Maki RA, Robin H, Muller W, Husain SR, Puri RK. 2002. Interleukin 4 receptor on human lung cancer: A molecular target for cytotoxin therapy. Clin Cancer Res (An official journal of the American Association for Cancer Research) 8: 3503 – 3511.en_US
dc.identifier.citedreferenceKennedy NJ, Davis RJ. 2003. Role of JNK in tumor development. Cell Cycle 2: 199 – 201.en_US
dc.identifier.citedreferenceKoller FL, Hwang DG, Dozier EA, Fingleton B. 2010. Epithelial interleukin‐4 receptor expression promotes colon tumor growth. Carcinogenesis 31: 1010 – 1017.en_US
dc.identifier.citedreferenceLi Z, Jiang J, Wang Z, Zhang J, Xiao M, Wang C, Lu Y, Qin Z. 2008. Endogenous interleukin‐4 promotes tumor development by increasing tumor cell resistance to apoptosis. Cancer Res 68: 8687 – 8694.en_US
dc.identifier.citedreferenceLoberg RD, Day LL, Dunn R, Kalikin LM, Pienta KJ. 2006. Inhibition of decay‐accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. Neoplasia 8: 69 – 78.en_US
dc.identifier.citedreferenceLoberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, Wojno K, Snyder LA, Yan L, Pienta KJ. 2007. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 67: 9417 – 9424.en_US
dc.identifier.citedreferenceLopez‐Bergami P, Huang C, Goydos JS, Yip D, Bar‐Eli M, Herlyn M, Smalley KS, Mahale A, Eroshkin A, Aaronson S, Ronai Z. 2007. Rewired ERK‐JNK signaling pathways in melanoma. Cancer Cell 11: 447 – 460.en_US
dc.identifier.citedreferenceMantovani A, Allavena P, Sica A, Balkwill F. 2008. Cancer‐related inflammation. Nature 454: 436 – 444.en_US
dc.identifier.citedreferenceMirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB, Liu S. 2002. Human survivin is negatively regulated by wild‐type p53 and participates in p53‐dependent apoptotic pathway. Oncogene 21: 2613 – 2622.en_US
dc.identifier.citedreferenceMizushima N, Yoshimori T. 2007. How to interpret LC3 immunoblotting. Autophagy 3: 542 – 545.en_US
dc.identifier.citedreferenceMyers JN, Yasumura S, Suminami Y, Hirabayashi H, Lin W, Johnson JT, Lotze MT, Whiteside TL. 1996. Growth stimulation of human head and neck squamous cell carcinoma cell lines by interleukin 4. Clin Cancer Res (An official journal of the American Association for Cancer Research) 2: 127 – 135.en_US
dc.identifier.citedreferenceProkopchuk O, Liu Y, Henne‐Bruns D, Kornmann M. 2005. Interleukin‐4 enhances proliferation of human pancreatic cancer cells: Evidence for autocrine and paracrine actions. Br J Cancer 92: 921 – 928.en_US
dc.identifier.citedreferenceRoca H, Varsos Z, Pienta KJ. 2008a. CCL2 protects prostate cancer PC3cells from autophagic death via phosphatidylinositol 3‐kinase/AKT‐dependent survivin up‐regulation. J Biol Chem 283: 25057 – 25073.en_US
dc.identifier.citedreferenceRoca H, Varsos ZS, Pienta KJ. 2009. CCL2 is a negative regulator of AMP‐activated protein kinase to sustain mTOR complex‐1 activation, survivin expression, and cell survival in human prostate cancer PC3cells. Neoplasia 11: 1309 – 1317.en_US
dc.identifier.citedreferenceShaulian E, Karin M. 2002. AP‐1 as a regulator of cell life and death. Nature Cell Biol 4: E131 – 136.en_US
dc.identifier.citedreferenceSokol CL, Barton GM, Farr AG, Medzhitov R. 2008. A mechanism for the initiation of allergen‐induced T helper type 2 responses. Nature Immunol 9: 310 – 318.en_US
dc.identifier.citedreferenceStremmel C, Greenfield EA, Howard E, Freeman GJ, Kuchroo VK. 1999. B7‐2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4‐dependent mechanism. J Exp Med 189: 919 – 930.en_US
dc.identifier.citedreferenceTodaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G, Medema JP, Stassi G. 2007. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin‐4. Cell Stem Cell 1: 389 – 402.en_US
dc.identifier.citedreferenceTodaro M, Zerilli M, Ricci‐Vitiani L, Bini M, Perez Alea M, Maria Florena A, Miceli L, Condorelli G, Bonventre S, Di Gesu G, De Maria R, Stassi G. 2006. Autocrine production of interleukin‐4 and interleukin‐10 is required for survival and growth of thyroid cancer cells. Cancer Res 66: 1491 – 1499.en_US
dc.identifier.citedreferenceTopp MS, Papadimitriou CA, Eitelbach F, Koenigsmann M, Oelmann E, Koehler B, Oberberg D, Reufi B, Stein H, Thiel E, et al. 1995. Recombinant human interleukin 4 has antiproliferative activity on human tumor cell lines derived from epithelial and nonepithelial histologies. Cancer Res 55: 2173 – 2176.en_US
dc.identifier.citedreferenceVaira V, Lee CW, Goel HL, Bosari S, Languino LR, Altieri DC. 2007. Regulation of survivin expression by IGF‐1/mTOR signaling. Oncogene 26: 2678 – 2684.en_US
dc.identifier.citedreferenceVivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis RJ, Wu H, Sawyers CL. 2007. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 11: 555 – 569.en_US
dc.identifier.citedreferenceWagner EF, Nebreda AR. 2009. Signal integration by JNK and p38 MAPK pathways in cancer development. Nature reviews. Cancer 9: 537 – 549.en_US
dc.identifier.citedreferenceWhitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE, Matese JC, Perou CM, Hurt MM, Brown PO, Botstein D. 2002. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 13: 1977 – 2000.en_US
dc.identifier.citedreferenceWu D, Molofsky AB, Liang HE, Ricardo‐Gonzalez RR, Jouihan HA, Bando JK, Chawla A, Locksley RM. 2011. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 332: 243 – 247.en_US
dc.identifier.citedreferenceYoshimoto T, Yasuda K, Tanaka H, Nakahira M, Imai Y, Fujimori Y, Nakanishi K. 2009. Basophils contribute to T(H)2‐IgE responses in vivo via IL‐4 production and presentation of peptide‐MHC class II complexes to CD4+ T cells. Nat Immunol 10: 706 – 712.en_US
dc.identifier.citedreferenceYu SJ, Kim HS, Cho SW, Sohn J. 2004. IL‐4 inhibits proliferation of renal carcinoma cells by increasing the expression of p21WAF1 and IRF‐1. Exp Mol Med 36: 372 – 379.en_US
dc.identifier.citedreferenceAltieri DC. 2008. Survivin, cancer networks and pathway‐directed drug discovery. Nature reviews. Cancer 8: 61 – 70.en_US
dc.identifier.citedreferenceArguello F, Baggs RB, Frantz CN. 1988. A murine model of experimental metastasis to bone and bone marrow. Cancer Res 48: 6876 – 6881.en_US
dc.identifier.citedreferenceChang TL, Peng X, Fu XY. 2000. Interleukin‐4 mediates cell growth inhibition through activation of Stat1. J Biol Chem 275: 10212 – 10217.en_US
dc.identifier.citedreferenceChen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, Turner JR, Fu YX, Romero IL, Lengyel E, Peter ME. 2010. CD95 promotes tumour growth. Nature 465: 492 – 496.en_US
dc.identifier.citedreferenceConticello C, Pedini F, Zeuner A, Patti M, Zerilli M, Stassi G, Messina A, Peschle C, De Maria R. 2004. IL‐4 protects tumor cells from anti‐CD95 and chemotherapeutic agents via up‐regulation of antiapoptotic proteins. J Immunol 172: 5467 – 5477.en_US
dc.identifier.citedreferenceDavis RJ. 2000. Signal transduction by the JNK group of MAP kinases. Cell 103: 239 – 252.en_US
dc.identifier.citedreferenceDecker T, Bogner C, Oelsner M, Peschel C, Ringshausen I. 2010. Antiapoptotic effect of interleukin‐2 (IL‐2) in B‐CLL cells with low and high affinity IL‐2 receptors. Ann Hematol 89: 1125 – 1132.en_US
dc.identifier.citedreferenceDi Stefano AB, Iovino F, Lombardo Y, Eterno V, Hoger T, Dieli F, Stassi G, Todaro M. 2010. Survivin is regulated by interleukin‐4 in colon cancer stem cells. J Cell Physiol 225: 555 – 561.en_US
dc.identifier.citedreferenceFaderl S, Harris D, Van Q, Kantarjian HM, Talpaz M, Estrov Z. 2003. Granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia. Blood 102: 630 – 637.en_US
dc.identifier.citedreferenceFerte C, Andre F, Soria JC. 2010. Molecular circuits of solid tumors: Prognostic and predictive tools for bedside use. Nat Rev Clin Oncol 7: 367 – 380.en_US
dc.identifier.citedreferenceFukushi J, Ono M, Morikawa W, Iwamoto Y, Kuwano M. 2000. The activity of soluble VCAM‐1 in angiogenesis stimulated by IL‐4 and IL‐13. J Immunol 165: 2818 – 2823.en_US
dc.identifier.citedreferenceGlinsky GV, Berezovska O, Glinskii AB. 2005. Microarray analysis identifies a death‐from‐cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115: 1503 – 1521.en_US
dc.identifier.citedreferenceGocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL, Berman T, Joyce JA. 2010. IL‐4 induces cathepsin protease activity in tumor‐associated macrophages to promote cancer growth and invasion. Genes Dev 24: 241 – 255.en_US
dc.identifier.citedreferenceGooch JL, Christy B, Yee D. 2002. STAT6 mediates interleukin‐4 growth inhibition in human breast cancer cells. Neoplasia 4: 324 – 331.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.